Ottiliavej 9 DK-2500 Valby Copenhagen Tlf +45 36 30 13 11 Fax +45 36 43 82 62 E-mail investor@lundbeck.com www.lundbeck.com



Release No 335

22 April 2008

H. Lundbeck A/S held its Annual General Meeting on 22 April 2008 at the company's registered office

At the general meeting note was taken of the report by the Supervisory Board on the activities of the company during the previous year, the Annual Report was approved, and the Supervisory Board and Executive Management were discharged from liability.

The general meeting approved the dividend of DKK 2.56 per share of DKK 5 nominal value proposed by the Supervisory Board.

Per Wold-Olsen, Thorleif Krarup, Peter Kürstein, Mats Pettersson and Jes Østergaard were all re-elected to the Supervisory Board. Egil Bodd was elected as a new board member. Immediately after the general meeting the Supervisory Board elected Per Wold-Olsen Chairman and Thorleif Krarup Deputy Chairman of the Supervisory Board.

After having elected its Chairman and Deputy Chairman, the Supervisory Board appointed members for the Audit Committee and the Remuneration Committee.

Peter Kürstein and Thorleif Krarup were re-elected as members of the Audit Committee. Egil Bodd was elected as new member of the Audit Committee. Per Wold-Olsen, Jes Østergaard and Mats Pettersson were re-elected as members of the Remuneration Committee.

The Supervisory Board of H. Lundbeck A/S will hereafter comprise:

- Per Wold-Olsen
- Thorleif Krarup
- Peter Kürstein
- Mats Pettersson
- Jes Østergaard
- Egil Bodd
- Birgit Bundgaard Rosenmeier (employee representative)
- Jens Møller Mayntzhusen (employee representative)
- Kim Rosenville Christensen (employee representative)

Deloitte Statsautoriseret Revisionsaktieselskab was re-appointed as the company's auditor.

H. Lundbeck A/S

Ottiliavei 9 DK-2500 Valby Copenhagen Fax +45 36 43 82 62

Tlf +45 36 30 13 11

E-mail investor@lundbeck.com www.lundbeck.com



The Supervisory Board's proposed resolutions under item 6 of the agenda were adopted. Consequently, a resolution was adopted to reduce the share capital of the company by DKK 51,966,745 nominal value of the company's holding of treasury shares acquired from shareholders of the company as part of the implementation of share buyback programmes. A new Article 4.4 was inserted into the Articles of Association, pursuant to which the Supervisory Board is authorised in the period until 2013 to issue warrants granting a right to subscribe for up to nominally DKK 25,000,000 in the company for the benefit of the Executive Management, senior employees and other employees of the company or its subsidiaries. The Supervisory Board was also authorised to let the company acquire treasury shares in compliance with section 48 of the Danish Public Companies Act. Overall guidelines for incentive remuneration of the Executive Management were approved and, as a result, a new provision was inserted as Article 5.6 of the Articles of Association. Finally, the chairman of the general meeting was authorised to make such changes in and supplements to the resolutions adopted by the general meeting and the notification to the Danish Commerce and Companies Agency as may be requested by the Commerce and Companies Agency in connection with its registration of the amendments made.

No other business was transacted at the general meeting.

Supervisory Board

The content of this release will have no influence on the Lundbeck Group's financial result for 2008.

Lundbeck contacts

Investors:

Jacob Tolstrup Director

+45 36 43 30 79

Palle Holm Olesen Head of Investor Relations +45 36 43 24 26

Stock Exchange Release No 335 – 22 April 2008

Media:

Anders Schroll

Head of Communication

+45 36 43 20 81

Jens Højbjerg

Media Relations Manager

+45 36 43 28 33

H. Lundbeck A/S

Ottiliavej 9 DK-2500 Valby Copenhagen

Tlf +45 36 30 13 11 Fax +45 36 43 82 62 E-mail investor@lundbeck.com www.lundbeck.com



About Lundbeck

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.5 billion or USD 2.0 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com